We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Amarantus Bioscience Holdings (AMBS) is a biotechnology company developing treatments and diagnostics for diseases in the areas of neurology, regenerative medicine and orphan diseases through its subsidiaries. AMBS acquired the rights to the Engineered Skin Substitute program (ESS), a regenerative m... Amarantus Bioscience Holdings (AMBS) is a biotechnology company developing treatments and diagnostics for diseases in the areas of neurology, regenerative medicine and orphan diseases through its subsidiaries. AMBS acquired the rights to the Engineered Skin Substitute program (ESS), a regenerative medicine-based approach for treating severe burns with full-thickness autologous skin grown in tissue culture that is being pursued by AMBS' wholly-owned subsidiary Cutanogen Corporation. AMBS' wholly-owned subsidiary MANF Therapeutics, Inc. owns key intellectual property rights and licenses from a number of prominent universities related to the development of the therapeutic protein known as mesencephalic astrocyte-derived neurotrophic factor ("MANF"). MANF Therapeutics, Inc. is developing MANF-based products as treatments for brain and ophthalmic disorders. MANF was discovered by the Company's Chief Scientific Officer John Commissiong, PhD. Dr. Commissiong discovered MANF from AMBS' proprietary discovery engine PhenoGuard. AMBS sold subsidiary Breakthrough Diagnostics to Todos Medical Ltd. in July of 2020. The Company also owns 51% of hemp/CBD company Hempori. Show more
Full US use of ANDiS 350 extraction systems would increase US daily testing capacity by 25% 3D Med extraction capacity increased by 1,000,000 kits per week Extraction reagent and automation...
Amarantus Acquires Majority Interest in CBD Wellness Company Hempori Strong customer retention at both stores in Dallas, TX with growing online presence Focus...
Amarantus Sub Elto Pharma Gets Notice of Allowance Covering Use of Eltoprazine Combined with CBD to Treat Parkinson’s Disease Patent extends patent coverage for eltoprazine to...
Amarantus Enters Into Agreement to License Diverse Therapeutics Portfolio to CBD-focused Emerald Organic Products Amarantus is receiving Emerald Preferred Stock with a minimum value of...
Amarantus Engages Evolution Venture Partners to Evaluate Strategic Alternatives for Expansion into the Legal Hemp Industry New York, NY -- May 28, 2019 -- InvestorsHub NewsWire...
Amarantus Provides 2019 Roadmap New York, NY -- January 7, 2019 -- InvestorsHub NewsWire -- Amarantus Bioscience Holdings, Inc. (OTC Pink: AMBS) (the...
Coeptis Pharma Enters into Agreement to Acquire Elto Pharma New York, NY and Wexford, PA -- November 28, 2018 -- InvestorsHub NewsWire -- Coeptis...
Amarantus Provides Corporate Update New York, NY -- July 20, 2018 -- InvestorsHub NewsWire -- Amarantus Bioscience Holdings, Inc. (OTC Pink: AMBS) (the...
MANF Therapeutics Announces Positive MANF Pre-Clinical Data in Alpha-Synuclein Model of Parkinson's Disease Published in Peer-Reviewed Journal Experimental...
MANF Therapeutics Announces Independent Publication of Positive Data for MANF in Traumatic Brain Injury Animal Model New York, NY -- June 11, 2018 -- InvestorsHub NewsWire...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0 | 0 | 0.0002 | 0.0002 | 0.0002 | 614 | 0.0002 | CS |
4 | -0.0008 | -80 | 0.001 | 0.001 | 1.0E-6 | 79391 | 0.00034223 | CS |
12 | 0.000199 | 19900 | 1.0E-6 | 0.0401 | 1.0E-6 | 123923 | 0.00016409 | CS |
26 | 0.0001 | 100 | 0.0001 | 0.0401 | 1.0E-6 | 81951 | 0.00015027 | CS |
52 | -0.00045 | -69.2307692308 | 0.00065 | 0.0401 | 1.0E-6 | 735037 | 0.00092816 | CS |
156 | -0.0068 | -97.1428571429 | 0.007 | 0.0401 | 1.0E-6 | 1692584 | 0.00372234 | CS |
260 | -0.0148 | -98.6666666667 | 0.015 | 0.0401 | 1.0E-6 | 1437058 | 0.00597798 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions